The Career Development Program of the Mayo Clinic SPORE in Pancreatic Cancer has been exclusively targeted to junior faculty career development. In the next funding period, we propose to include both junior faculty and early mid-career faculty who will commit to mentored career development in translational pancreatic cancer research. One of the starkest realities facing the contemporary research community is the paucity of experienced investigators involved in translational pancreatic cancer research. In the past funding period, we had recognized the importance of attracting and nurturing individuals who would be committed to a pancreatic cancer research career. We successfully engaged and encouraged junior faculty, who have fulfilled the objective of this Program and the spirit of the SPORE program. Two of our past Career Development Awardees have developed successfully to become Leaders of full translational research projects in this current competing renewal application. Our goal will be extended to increase this pool and grow the community of experienced pancreatic cancer researchers by attracting early mid-career faculty as well. The core of senior pancreatic cancer researchers at Mayo Clinic, combined with highly productive investigators in other areas of cancer research, will form mentoring teams. Mayo Clinic has, by its seamless blend of patient care and basic and applied research facilities, an environment conducive to this type of mentored translational research. Mayo Clinic also has very competitive recruitment to faculty positions. There thus exists a continuous pool of outstanding scientists and clinicians (including talented female and minority investigators) who are early in their careers and who need exactly an impetus such as that offered by our SPORE's proposed Career Development Program to engage in translational research with a focus on pancreatic cancer. We will continue to implement our formal mechanisms for recruiting, selecting and evaluating awardees, and will ensure that awardees are integrated into the SPORE research environment. In all cases, we expect that recipients in the Career Development Program will build upon the resources allocated to them to develop independent funding in pancreatic cancer research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA102701-09
Application #
8316347
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2011-09-01
Budget End
2012-08-31
Support Year
9
Fiscal Year
2011
Total Cost
$113,279
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Chaffee, Kari G; Oberg, Ann L; McWilliams, Robert R et al. (2018) Prevalence of germ-line mutations in cancer genes among pancreatic cancer patients with a positive family history. Genet Med 20:119-127
Shroff, Rachna T; Hendifar, Andrew; McWilliams, Robert R et al. (2018) Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation. JCO Precis Oncol 2018:
McWilliams, Robert R; Wieben, Eric D; Chaffee, Kari G et al. (2018) CDKN2A Germline Rare Coding Variants and Risk of Pancreatic Cancer in Minority Populations. Cancer Epidemiol Biomarkers Prev 27:1364-1370
Supekar, Nitin T; Lakshminarayanan, Vani; Capicciotti, Chantelle J et al. (2018) Synthesis and Immunological Evaluation of a Multicomponent Cancer Vaccine Candidate Containing a Long MUC1 Glycopeptide. Chembiochem 19:121-125
Cohen, Joshua D; Li, Lu; Wang, Yuxuan et al. (2018) Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science 359:926-930
Zhang, Mingfeng; Lykke-Andersen, Soren; Zhu, Bin et al. (2018) Characterising cis-regulatory variation in the transcriptome of histologically normal and tumour-derived pancreatic tissues. Gut 67:521-533
Kanamori, Karina S; de Oliveira, Guilherme C; Auxiliadora-Martins, Maria et al. (2018) Two Different Methods of Quantification of Oxidized Nicotinamide Adenine Dinucleotide (NAD+) and Reduced Nicotinamide Adenine Dinucleotide (NADH) Intracellular Levels: Enzymatic Coupled Cycling Assay and Ultra-performance Liquid Chromatography (UPLC)-Mass Bio Protoc 8:
Hu, Chunling; Hart, Steven N; Polley, Eric C et al. (2018) Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer. JAMA 319:2401-2409
Orozco, Carlos A; Martinez-Bosch, Neus; Guerrero, Pedro E et al. (2018) Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor-stroma crosstalk. Proc Natl Acad Sci U S A 115:E3769-E3778
Radecki Breitkopf, Carmen; Wolf, Susan M; Chaffee, Kari G et al. (2018) Attitudes Toward Return of Genetic Research Results to Relatives, Including After Death: Comparison of Cancer Probands, Blood Relatives, and Spouse/Partners. J Empir Res Hum Res Ethics 13:295-304

Showing the most recent 10 out of 336 publications